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Abstract Colorectal cancer is the third most common cancer
worldwide. A significant proportion of patients presents with
unresectablemetastatic disease or developsmetachronousme-
tastases following surgical resection of the primary tumor. The
prognosis of the disease has improved over the past two de-
cades, with extended multimodality treatment options and the
development of increasingly intensified chemotherapy regi-
mens that now typically include targeted biologics. A recent
advance in therapy is a treatment regimen composed of three
chemotherapeutic agents (i.e., triplet chemotherapy: 5-
fluorouracil [5-FU]/leucovorin [LV], oxaliplatin, and
irinotecan; FOLFOXIRI) in combination with the vascular
endothelial growth factor inhibitor bevacizumab. This regi-
men has been shown to elicit significantly improved objective
response rates andmedian progression-free survival compared
with 5-FU/LV and irinotecan in combination with
bevacizumab. However, triplet chemotherapy has been asso-
ciated with increased rates of chemotherapy-related adverse
events, and treatment-emergent adverse events should be
properly managed to minimize treatment interruption or dis-
continuation. We present herein a review of clinical studies
evaluating the safety and efficacy of FOLFOXIRI with
bevacizumab in metastatic colorectal cancer, and propose a
practical guide for the management of adverse events associ-
ated with the regimen.
Key Points
Triplet chemotherapy + bevacizumab improves efficacy 
compared with doublet chemotherapy + bevacizumab in 
patients with metastatic colorectal cancer 
Adverse events may be effectively managed with early 
recognition and rapid intervention 
1 Introduction
A large proportion of patients diagnosed with colorectal can-
cer (CRC) will develop metastatic disease (mCRC). The ma-
jority (20–90 %) of metastases are found in the liver (up to
25 % of which are synchronous), and 10–20 % are found in
the lung [1–3]. Studies have shown that, in suitable patients,
curative resection of colorectal metastases is a reasonable goal
[4, 5] and dramatically improves survival prospects. Chemo-
therapy treatment may facilitate tumor resection, even in pre-
viously nonresectable tumors from hepatic metastases of CRC
[6, 7].
Chemotherapy for CRC has evolved over time to improve
patient outcomes compared with earlier regimens. Standard
two-drug chemotherapeutic regimens include 5-fluorouracil
(5-FU)/leucovorin (LV) plus either irinotecan (FOLFIRI) or
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oxaliplatin (FOLFOX) [8, 9]. The addition of a third chemo-
therapeutic agent (i.e., FOLFIRI combined with oxaliplatin or
FOLFOX combined with irinotecan), resulting in a
FOLFIRINOX or a FOLFOXIRI regimen, respectively, has
recently been evaluated in clinical trials [10–17]. Phase II
studies of triplet chemotherapy on a biweekly schedule
showed promising efficacy with regard to both progression-
free survival (PFS) (e.g., 10.4 months [11], 10.8 months [12])
and overall survival (OS) (e.g., 26.5 months [11], 28.4 months
[12]).
Moreover, a more recent study comparing FOLFIRINOX
to standard 2-agent chemotherapy (FOLFIRI or FOLFOX4)
or other intensified doublet regimens with either high-dose
irinotecan (FOLFIRI-HD) or oxaliplatin (FOLFOX7) re-
vealed that patients in the FOLFIRINOX arm had the longest
numerical PFS (standard: 9.2 months [95 % confidence inter-
val (CI): 6.8–13.4]; FOLFIRI-HD: 12.1 months [95 % CI:
10.3–16.6]; FOLFOX7: 8.5 months [95 % CI: 6.4–10.9];
FOLFIRINOX: 14.1 months [95 % CI: 11.2–21.7]) and OS
(standard: 17.7 months [95 % CI: 13.7–43.0]; FOLFIRI-HD:
29.4 months [95 % CI: 26.1–42.4]; FOLFOX7: 26.9 months
[95 % CI: 18.7–45.0]; FOLFIRNIOX: 48.8 months [95 % CI:
21.9–not reached]) compared with patients in the other arms
[17]. FOLFIRINOX, furthermore, elicited the highest 3-year
OS rate (58 % [95 % CI 38–74] vs. 38 % [95 % CI 21–55],
43 % [95 % CI 26–59], 44 % [95 % CI 25–61] in the control,
FOLFIRI-HD, and FOLFOX7 arms, respectively) [17]. Addi-
tionally, one phase III study showed that FOLFOXIRI led to a
numerically greater time to disease progression (8.4 vs.
6.9 months, p=0.17), OS (21.5 vs. 19.5 months; p=0.337),
and response rate (43 vs. 33.6 %; p=0.168) compared with
FOLFIRI [14], while another study showed that FOLFOXIRI
conferred a significant improvement in PFS (9.8 vs.
6.9 months; hazard ratio [HR]=0.63; p=0.006) and OS
(22.6 vs. 16.7 months; HR=0.70; p=0.032) [13].
Common grade 3/4 adverse events associated with triplet
chemotherapy include neutropenia (33–59 %) [12–14, 17],
diarrhea (16–30 %) [12–14, 17], mucositis/stomatitis (5–
10 %) [12–14, 17], thrombocytopenia (2-13 %) [12–14, 17],
neurotoxicity (2–17%) [12–14, 17], nausea/vomiting (0–7 %)
[12–14, 17], asthenia (6–13 %) [13–17], and alopecia (0–
32 %) [12–14]. Adverse events for which the FOLFOXIRI
arm had a significantly higher frequency than the FOLFIRI
arm were grade 3/4 alopecia (32 vs. 12 %, p=0.0001) [14],
diarrhea (27.7 vs. 10.9 %, p=0.0001) [14], neurosensory tox-
icity (5.8 vs. 0 %, p=0.001) [14], and neutropenia [50 vs. 28,
p<0.001) [13]. The dosing schedule for standard triplet che-
motherapy is illustrated in Table 1.
The addition of a targeted biologic agent (i.e., the vascular
endothelial growth factor inhibitor bevacizumab or the epider-
mal growth factor receptor [EGFR] inhibitors cetuximab or
panitumumab in patients with mCRC that is wild-type for
RAS [KRAS/NRAS exon 2–4]) has been another advance to
standard chemotherapy doublets [18–23]. Improved rates of
response, PFS and OS have been reported for doublet +
targeted biologic treatments compared with doublets alone in
clinical trials [18–23]. FOLFOX or FOLFIRI in combination
with bevacizumab (first-line or second-line) [4, 24, 25] or in
combination with cetuximab or panitumumab are indicated
for first-line, RAS-wild-type mCRC [4, 26–31], and have be-
come widely adopted for the first-line treatment of mCRC.
The next step in the evolution of chemotherapy for mCRC
was the combination of a biologic agent with triplet chemo-
therapy. This combination has recently been explored to eval-
uate clinical outcomes and to potentially increase opportuni-
ties for surgical resection. Clinical studies have demonstrated
the feasibility of combining cetuximab or panitumumab and
FOLFOXIRI with promising response and resection rates;
however, significant toxicity (grade 3/4) was observed
[32–36]. Commonly reported grade ≥3 adverse events includ-
ed diarrhea (25–94 %) [32–36], neutropenia (23–48 %) [32,
35, 36], nausea/vomiting (5–17 %) [32–36], and stomatitis
(10–14 %) [34, 35]. Dose reductions to mitigate adverse
events were common [33, 34]. Alternatively, given the well-
described and tolerable safety profile of bevacizumab, the
combination of triplet chemotherapy with bevacizumab has
also been studied as a treatment option.
FOLFOXIRI with bevacizumab has recently been evaluat-
ed in clinical settings, and has been associated with improved
survival and/or activity compared with two-drug regimens
combined with bevacizumab [37–41]. However, the observed
incidence rates of certain adverse events that are associated
with the regimen (i.e., diarrhea, nausea/vomiting, neutropenia,
stomatitis, and neutropenia) have resulted in treatment delays
and dose reductions, and have led to debate regarding whether
the regimen should be considered a standard of care [42].
Herein, we review recently published efficacy and safe-
ty outcomes from phase II and phase III clinical trials of
bevacizumab in combination with triplet chemotherapeu-
tic regimens in patients with mCRC. Additionally, we
propose a practical guide for the management of common-
ly occurring adverse events to improve the tolerability of
the regimen.
Table 1 Triplet chemotherapy dosing schedule
Step Chemotherapeutic agent Dosea Duration (hours)
1 bevacizumab 5 mg/kg 0.5
2 irinotecan 165 mg/m2 1
3 oxaliplatin 85 mg/m2 2
3 I-leucovorin 200 mg/m2 2
4 5-fluorouracil 3200 mg/m2 48
aDoses are delivered intravenously in bi-weekly cycles
I-leucovorin, infusional leucovorin
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2 Clinical Studies
2.1 First-line FOLFOXIRI in Combination
with Bevacizumab for mCRC (FOIB)
Treatment composed of bevacizumab in combination
with triplet (FOLFOXIRI) chemotherapy for induction
(6-month maximum) therapy, followed by bevacizumab
maintenance therapy, was assessed in 57 patients [43].
The primary endpoint was PFS rate at 10 months from
study entry; secondary endpoints included response rate
and safety profile.
Approximately half (53 %) of the patients had liver-only
metastases, and KRAS and BRAFmutations were identified in
38 % and 18 % of patients, respectively. The study met its
primary endpoint, with a PFS rate at 10 months of 74% (95 %
CI: 62–85 %). Overall response rate was 77 % (95 % CI: 66–
88 %); median PFS and OS were 13.1 months and
30.9 months, respectively. Among patients with liver-only
metastases at baseline (n=30), median PFS was 16.0 months
(95 % CI: 12.5–21.5), the response rate was 80% (n=24), and
the radical resection rate was 40 % (n=12). No associations
between KRAS and BRAF mutations and treatment response
were found.
Neutropenia, diarrhea, and hypertension were the most
common grade 3/4 adverse events reported, which is similar
to other clinical trials (Table 2). There were no treatment-
related deaths, and grade 4 toxicities were few (with the ex-
ception of uncomplicated neutropenia). Of the 14 patients
who discontinued induction treatment, two discontinued be-
cause of adverse events. All 37 patients who continued to
maintenance therapy eventually discontinued treatment; of
these, two were due to adverse events.
2.2 Bevacizumab in Combination with mFOLFOX6
or FOLFOXIRI in Patients with Unresectable
Liver-limited mCRC (OLIVIA)
OLIVIA assessed the efficacy of bevacizumab in combination
wi th ei ther FOLFOXIRI or modif ied FOLFOX6
(mFOLFOX6) in 80 previously untreated patients with CRC
and initially unresectable liver metastases [37]. The primary
endpoint was the overall resection rate for first resections.
Secondary endpoints included PFS, overall response rate,
and safety.
The majority of enrolled patients (94 %; n=75) had ≥3
metastatic lesions at baseline. Following treatment, a 12 %
difference in overall resection rate for first resection between
the FOLFOXIRI + bevacizumab and the mFOLFOX-6 +
bevacizumab groups was observed (61 % vs. 49 %, respec-
tively; difference 12 %, 95 % CI: 11–36 %). Overall, tumor
response rate was also higher (81 % [95 % CI: 65–91 %] vs.
62 % [95 % CI: 45–77 %]) and median PFS was numerically
longer (18.6 [95 % CI: 12.9–22.3] vs. 11.5 [95 % CI: 9.6–
13.6] months) in the FOLFOXIRI + bevacizumab group com-
pared with the mFOLFOX-6 + bevacizumab group,
respectively.
Adverse events grade ≥3 occurred in 95% of patients in the
triplet group and 84 % of patients in the doublet +
bevacizumab group, with neutropenia, diarrhea, and febrile
neutropenia as the most frequently reported (Table 2). Eight
patients in the FOLFOXIRI + bevacizumab group and 13
patients in the mFOLFOX6 + bevacizumab group
discontinued the study due to adverse events.
2.3 OPAL: A Study of Bevacizumab in Combination
with FOLFOXIRI in Patients with Previously Untreated
mCRC
The OPAL study evaluated the feasibility of administering
bevacizumab plus FOLFOXIRI followed by maintenance
with bevacizumab plus 5-FU/LV until disease progression to
treat 90 treatment-naive patients with unresectable mCRC
[44]. The primary endpoint was PFS; secondary endpoints
included OS, resectability rate, and safety.
At baseline, the majority of patients (57 %) had multiple
sites of metastases, and 39 % had metastases confined to the
liver. Overall, induction plus maintenance treatment led to a
median PFS of 11.1 months and OS of 32.2 months. These
results are similar to those of the TRIBE study (FOLFOXIRI
arm) [41]. Of the 24 patients (27 %) who underwent second-
ary tumor resections, 67%were considered curative (R0). The
R0 resection rate (18 %) was lower than that reported in the
FOIB study (26 %) [43], which may be attributed to the lower
proportion of patients with liver-limited metastases at baseline
in the OPAL study compared with the FOIB study (39 vs.
53 %).
The most frequently reported grade 3/4 adverse events
(≥10 %) during induction were leukopenia/neutropenia and
diarrhea (see Table 2). Due to adverse events, 16 % of patients
discontinued the study and 32 % of the patients required dose
reductions.
2.4 TRIBE: Combination Chemotherapy
and Bevacizumab as First-line Therapy in Treating
Patients with mCRC
Based on the favorable results of the FOIB phase II trial, the
phase III TRIBE study was initiated to compare FOLFOXIRI
+ bevacizumab with FOLFIRI + bevacizumab as a first-line
treatment in 508 patients with unresectable mCRC [39]. The
primary endpoint was PFS; secondary endpoints included re-
sponse rate, OS, resection rate for metastases, and safety.
At baseline, metastases were confined to the liver in 18.0%
of the triplet and 23.4 % of the doublet chemotherapy treat-
ment groups, and KRAS and BRAF mutations were found in
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39.4 % and 5.5 % of patients analyzed, respectively. In the
triplet arm, significantly more cycles were delayed (16.4 vs.
6.1 %, p<0.001) and more chemotherapy doses were reduced
(21.4 vs. 8.2 %, p<0.001) compared with the doublet chemo-
therapy arm. However, disease progression led to significantly
more discontinuations in the doublet than in the triplet chemo-
therapy treatment group (20.1 vs. 12.8 %, p=0.03).
An improvement in the objective response rate was ob-
served in the triplet + bevacizumab arm compared with the
doublet + bevacizumab arm (65 vs. 53 %, p=0.006). Likewise,
Table 2 Most common (≥3 of patients in any group) grade 3/4 AEs in phase II and phase III clinical studies of bevacizumab in combinationwith triplet
chemotherapy
Grade 3/4 AEs, n (%) Phase III study Phase II studies



















Neutropenia/leukopeniac 125 (50) 52 (21) 28 (49) 20 (50) 13 (35) 22 (24)
Febrile neutropenia 22 (9) 16 (6) 1 (2) 5 (13) 3 (8) 2 (2)
Diarrhea 47 (19) 27 (11) 8 (14) 12 (30) 5 (14) 9 (10)
Stomatitis/mucosal inflammationd 22 (9) 11 (4) 2 (4) 1 (3) 0 (0) 4 (4)
Nausea 7 (3) 8 (3) 2 (4) 2 (5) 0 (0) 6 (7)
Vomiting 11 (4) 8 (3) 0 (0) 3 (8) 1 (3) 7 (8)
Asthenia 30 (12) 23 (9) 4 (7) 1 (3) 0 (0) NR
Peripheral neuropathy/neurotoxicitye 13 (5) 0 (0) 1 (2) 1 (3) 0 (0) 6 (7)
Hypertension 13 (5) 6 (2.4) 6 (11) 0 (0) 2 (5) 3 (3)
VTE/DVTf 18 (7.2) 15 (5.9) 4 (7) 2 (5) 2 (5) 5 (6)
Constipation NR NR NR 0 (0) 2 (5) NR
Fatigue NR NR NR 3 (8) 1 (3) 3 (3)
a Grade ≥3
b Chemotherapeutic regimens for phase II and phase III studies:
• Bevacizumab (all studies): 5 mg/kg infusion on day 1, every 2 weeks
• TRIBE study
- FOLFIRI = irinotecan (180mg/m2 , 60-minute infusion) + leucovorin (200mg/m2 , 120-minute infusion) + fluorouracil (400mg/m2 bolus, followed by
a 46-hour continuous infusion: total dose 2400 mg/m2 ) every 2 weeks for up to 12 cycles
- FOLFOXIRI = irinotecan (165 mg/m2 , 60-minute infusion) + oxaliplatin (85 mg/m2 , 120-minute infusion)/leucovorin (200 mg/m2 , 120-minute
infusion) + fluorouracil (48-hour continuous infusion: total dose 3200 mg/m2 ) every 2 weeks for to 12 cycles
• OLIVIA study
- FOLFOXIRI: irinotecan (165 mg/m2 ) + oxaliplatin (85 mg/m2 ) + leucovorin (200 mg/m2 ) + 5-fluorouracil (3200 mg/m2 as a 46-hour continuous
infusion) on day 1, every 2 weeks
- mFOLFOX6: oxaliplatin (85mg/m2 ) + leucovorin (400mg/m2 ) + 5-fluorouracil (400mg/m2 bolus, followed by 2400mg/m2 as a 46-hour continuous
infusion on day 1, every 2 weeks).
• FOIB study
- Induction (maximum6months): FOLFOXIRI: irinotecan (165mg/m2 on day 1) + oxaliplatin (85mg/m2 on day 1) + leucovorin (200mg/m2 on day 1)
+ fluorouracil (3200 mg/m2 for 48-hour continuous infusion, starting on day 1 and repeated every 2 weeks)
• OPAL study
- Induction (cycles 1–12): FOLFOXIRI: oxaliplatin (85 mg/m2 , 2-hour infusion on day 1) + irinotecan (165 mg/m2 , 1-hour infusion on day 1) +
leucovorin (200 mg/m2 , 2-hour continuous infusion on day 1) + 5-fluorouracil (3200 mg/m2 , 48-hour continuous infusion on days 1–3)
c Neutropenia (TRIBE, OLIVIA, and FOIB studies); leucopenia/neutropenia (OPAL study)
d Stomatitis (TRIBE, FOIB, and OPAL studies); mucosal inflammation (OLIVIA study)
e Peripheral neuropathy (TRIBE and OLIVIA studies); neurotoxicity (FOIB and OPAL studies)
f VTE (TRIBE and OPAL studies); DVT (OLIVIA and FOIB studies)
AE, adverse event; DVT, deep vein thrombosis; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFOXIRI, 5-fluorouracil, leucovorin, oxaliplatin,
irinotecan; mFOLFOX6, 5-fluorouracil, leucovorin, oxaliplatin; NR, not reported; VTE, venous thromboembolism
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the median PFS increased to 12.1 months from 9.7 months
(hazard ratio [HR] for progression=0.75; 95 % CI: 0.62–
0.90; p=0.003) (Fig. 1). Subgroup analysis of the treatment
effect on PFS indicated that having received only a previous
adjuvant treatment significantly affected PFS (p=0.04). The
risk of progression analyzed according to Eastern Cooperative
Oncology Group (ECOG) performance status, primary tumor
site, time to metastases, liver-only disease, surgery on the pri-
mary tumor, Köhne index score, or KRAS or BRAF mutation
status was otherwise consistent, although a trend was observed
for improved outcomes for patients with BRAFmutations treat-
ed with FOLFOXIRI + bevacizumab. Furthermore, triplet +
bevacizumab conferred an OS benefit compared with doublet
+ bevacizumab (29.8 vs. 25.8 months, respectively; HR
for death, 0.80; 95 % CI: 0.65–0.98; p=0.03) [41]. The
treatment groups, however, did not have a significantly
different rate of R0 resection of metastases (FOLFOXIRI +
bevacizumab: 12 % vs. FOLFIRI + bevacizumab: 15 %;
p=0.33) [39].
No statistically significant differences were observed be-
tween treatment groups in the rates of serious adverse events
(20.4 vs. 19.7 %), death due to disease progression (48.4 vs.
55.9 %), or treatment-related toxicity (2.4 vs. 1.6 %); howev-
er, as expected, treatment intensification was associated with a
significant increase in grade 3/4 rates of neurotoxicity
(p<0.001), stomatitis (p=0.048), diarrhea (p=0.01), and neu-
tropenia (p<0.001) (see Table 2).
3 Overall Feasibility of Triplet Chemotherapy +
Bevacizumab
3.1 Feasibility for All Patients
Overall, data from phase II and phase III clinical studies indi-
cate that treatment with bevacizumab in combination with
triplet chemotherapy is feasible in patients with mCRC, and
no new safety signals were observed [37–39, 43]. While grade
Fig. 1 TRIBE phase III study:
Kaplan–Meier estimates of (a)
PFS [39] and (b) OS [41],





irinotecan; OS, overall survival;
PFS, progression-free survival. a.
Reprinted with permission [39].
b. Reprinted from The Lancet
Oncology, Vol 16, C Cremolini, F
Loupakis, C Antoniotti, Cristiana
Lupi, Elisa Sensi, Sara Lonardi,
Silvia Mezi, Gianluca Tomasello,
Monica Ronzoni, Alberto
Zaniboni, Giuseppe Tonini, C
Carlomagno, G Allegrini, S
Chiara, M D'Amico, C Granetto,





treatment of patients with
metastatic colorectal cancer:
updated overall survival and
molecular subgroup analyses of
the open-label, phase 3 TRIBE
study, 1306-1315, Copyright
(2015), with permission from
Elsevier [41]
297Targ Oncol (2016) 11:293–308
≥3 neutropenia, diarrhea, stomatitis, and peripheral neuropa-
thy were significantly higher with triplet compared with dou-
blet chemotherapy regimens in the phase III TRIBE study,
adverse events were considered manageable [39]. Incidences
of bevacizumab-related adverse events were similar to those
seen in previous studies of bevacizumab combined with che-
motherapy (e.g., irinotecan, 5-FU, and LV, or oxaliplatin-
based doublets) in the first-line setting [30, 31, 45].
Due to the known toxicity associated with FOLFOXIRI +
bevacizumab, an early evaluation of response may be impor-
tant, so that patients who do not benefit from this regimenmay
avoid unnecessary toxicity and delay in initiating another line
of treatment. An analysis of the TRIBE results revealed that a
significantly higher proportion of patients in the FOLFOXIRI
+ bevacizumab arm compared with the FOLFIRI +
bevacizumab arm experienced early tumor shrinkage of
≥20 % (62.7 vs. 51.9 %, p=0.025) and depth of response
(43.4 vs. 37.8 %, p=0.003), and demonstrated an association
between these parameters and PFS, post-progression survival,
and OS [40].
3.2 Feasibility in the Conversion Setting (i.e., to Render
Patients with Unresectable mCRC Liver Metastases
Potentially Resectable)
Because of the potential impact of bevacizumab on wound
healing and liver regeneration, the addition of bevacizumab
to triplet regimens comes with an increased risk of periopera-
tive toxicity, although recent studies have shown safe use of
bevacizumab if treatment breaks, beginning 4–6 weeks prior
to surgery and lasting through complete wound healing are
observed [46]. Results of recent studies have shown that this
regimen has activity in eliciting a pathological response of
liver metastases without increasing liver toxicity, and that
the risk of perioperative complications may be reduced by
discontinuing bevacizumab prior to surgery [37, 47].
A study that evaluated hepatic tissue from patients
showed that FOLFOXIRI + bevacizumab elicited a greater
histopathologic response than chemotherapy alone (either
FOLFOXIRI or XELOXIRI) with regard to tumor regres-
sion grades of 1, 2, and 3 (FOLFOXIRI + bevacizumab:
63 %; chemotherapy: 28 %; p=0.033) [47]. Furthermore,
a tumor necrosis exploratory cutoff of ≥50 % was
achieved in a greater proportion of patients who received
bevacizumab compared with those who did not
(FOLFOXIRI + bevacizumab: 52 %; chemotherapy:
12.5 %; p=0.017), while there was no significant differ-
ence in liver toxicity as measured by sinusoidal dilation,
parenchymal steatosis, steatohepatitis, and parenchymal ne-
crosis. Notably, the replacement of liver metastases by a
necrosis rate of ≥50 % conferred a PFS benefit compared
with patients with a necrosis rate of <50 % (HR=0.38;
95 % CI: 0.19–0.97; p=0.041).
In the OLIVIA study of patients with unresectable liver-
only metastasis, data suggested that secondary tumor resection
was occasionally feasible in patients treated with FOLFOXIRI
+ bevacizumab [37]. Response rates, primary resection rates,
and PFS all showed improvement compared with treatment
with double t chemotherapy (i .e . , mFOLFOX6 +
bevacizumab). Notably, OLIVIA achieved these results in an
unselected patient population with regard to molecular factors
and extent of disease. While treatment-related toxicity
was increased with triplet chemotherapy (i.e., FOLFOXIRI
+ bevacizumab), no new or unexpected safety signals were
observed. Additionally, data from the surgical safety popula-
tion (n=25, FOLFOXIRI + bevacizumab group; n=19,
mFOLFOX6 + bevacizumab group) showed comparable in-
cidences of all-grade surgery-related adverse events with
FOLFOXIRI + bevacizumab compared with the mFOLFOX6
+ bevacizumab group (60 vs. 79 %), with no anastomotic
leaks following primary tumor resection. This is similar to
previous observations [46, 48] that showed that by
discontinuing bevacizumab 4–5 weeks prior to surgery, a
marked increase in postoperative bleeding and wound-
healing complications (which are potential bevacizumab-
related adverse events that could interfere with perioperative
treatment continuation) may be avoided, and resection of liver
metastases may thus be safely performed.
3.3 Perspective on the Importance of Bevacizumab +
Triplet Chemotherapy for Patients Eligible for Aggressive
Chemotherapy
3.3.1 RAS Wild-type Disease
Data from a meta-analysis indicated that there was a
benefit to using EGFR inhibitors with doublet chemo-
therapy as first-line therapy in patients with RAS wild-
type mCRC [21, 49]. Furthermore, results from the
FIRE-3 study, in which patients with KRAS exon2
wild-type mCRC were treated with FOLFIRI in combi-
nation with either bevacizumab or cetuximab, showed
that while response rate and PFS were similar between
treatment groups, median OS was longer in the
cetuximab group than in the bevacizumab group (28.7
vs. 25.0 months; HR 0.77, 95 % CI: 0.62–0.96; p=0·
017) [45]. However, the first-line treatment of RAS
wild-type mCRC with doublet chemotherapy in combi-
nation with a targeted agent is still a matter of debate,
as data from relevant prospective trials are still pending.
Thus far, in the phase III TRIBE study, a similar pro-
portion of patients in both FOLFIRI + bevacizumab
(39 %) and FOLFOXIRI + bevacizumab (37 %) arms
had KRAS wild-type disease, and subgroup analyses
showed that the treatment effect (i.e., reduced the risk
of disease progression for patients receiving FOLFIXIRI
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+ bevacizumab compared with those receiving FOLFIRI
+ bevacizumab) was independent of KRAS mutation
status.
3.3.2 BRAF-mutated Disease
The BRAF V600E mutation is considered a strong prognostic
marker in mCRC, and a putative predictive role of this BRAF
mutation for resistance to anti-EGFR treatment has been hy-
pothesized based on retrospective analyses. However, the hy-
pothesis has not been universally accepted despite two recent
meta-analyses showing that there is no clinically relevant ben-
efit for the addition of an EGFR antibody to chemotherapy for
patients with BRAF-mutated disease [50, 51]. The use of the
BRAF V600E mutation as a prognostic marker has been dem-
onstrated in survival analyses of mCRC first-line trials, in
which patients with BRAF-mutated mCRC had a worse prog-
nosis than those without BRAF mutations [52–54]. Further,
results in the TRIBE study indicated that BRAF-mutated dis-
ease (5.5 % of the study population) is an adverse prognostic
factor for both PFS and OS (univariate analysis) [39].
Data suggest that triplet chemotherapy + bevacizumab may
be a reasonable option in patients withBRAF-mutated disease.
The TRIBE study, for example, showed that treatment effect
was not significantly different between BRAF-wild-type and
BRAF-mutant patient subgroups [41]. Moreover, in a phase II
trial of 15 patients with BRAF-mutatedmCRCwhowere treat-
ed with first-line FOLFOXIRI + bevacizumab, the 6-month
progression-free rate (primary endpoint), median PFS, and OS
were 73 %, 9.2 months, and 24.1 months, respectively [55].
These results, however, should be interpreted with caution due
to small sample sizes.
4 Ongoing Trials of Triplet Chemotherapy
in Combination with Targeted Biologics
4.1 Anti-EGFR Agents
Anti-EGFR agents have shown efficacy in patients with
mCRC, and cetuximab and panitumumab are thus indicated,
in combination with doublet chemotherapy, for the treatment
of patients with mCRC [26, 27]. These agents are currently
being investigated in several phase II clinical trials of anti-
EGFR agents in combination with triplet chemotherapy in
patients with previously untreated mCRC. These include
MACBETH (FOLFOXIRI induction + cetuximab and main-
tenance cetuximab or bevacizumab; NCT02295930; primary
completion date: April 2015), FOCULM (FOLFOXIRI ±
cetuximab in patients with liver metastases only;
NCT02063529; primary completion date: February 2016),
VOLFI (FOLFOXIRI ± panitumumab; NCT01328171; pri-
mary completion date: December 2016), and CELIM2
(FOLFOXIRI or FOLFIRI + cetuximab in patients with
RAS /BRAF wild-type tumors and FOLFOXIRI ±
bevacizumab in patients with RAS/BRAF mutant tumors;
NCT01802645; primary completion date: July 2017).
4.2 Bevacizumab (Fig. 2)
4.2.1 Efficacy of FOLFOX + Bevacizumab in Combination
with Irinotecan in the Treatment of Patients with mCRC
(CHARTA, NCT01321957)
CHARTA is a randomized phase II trial that seeks to
evaluate the activity of an intensified first-line therapy
for mCRC (FOLFOXIRI + bevacizumab) compared with
standard treatment (FOLFOX + bevacizumab) in 250 pa-
tients with mCRC or recurrent CRC (Fig. 2a) [38]. Treat-
ment will be administered until disease progression, intol-
erable toxicity, secondary resection, or for a maximum of
12 cycles (6 months). After 6 months of treatment and/or
no disease progression, patients will continue with a main-
tenance regimen with bevacizumab and a fluoropyrimidine
(choice of 5-FU or capecitabine at the investigator’s dis-
cretion) for up to 12 months in the absence of progression
or intolerable toxicity. The maximum treatment duration,
including maintenance therapy, is 18 months. The primary
endpoint is PFS at 9 months. Notably, the CHARTA study
includes a secondary endpoint of health-related quality of
life (as assessed via the European Organisation for Re-
search and Treatment of Cancer QLQ-C30, QLQ-CR29,
and QLQ-CIPN20 scales), which may add valuable infor-
mation regarding patient-reported outcomes of triplet che-
motherapy + bevacizumab. Recruitment was completed in
December 2014.
4.2.2 First-line FOLFOXIRI + Bevacizumab, Followed
by Reintroduction of FOLFOXIRI + Bevacizumab
at Progression vs. FOLFOX + Bevacizumab Followed
by FOLFIRI + Bevacizumab in mCRC (TRIBE-2,
NCT02339116)
The primary endpoint of the TRIBE-2 study is Progression-
free survival 2 (PFS2); the planned study length is approxi-
mately 4.5 years (Fig. 2b). The first patient was enrolled in
February 2015, and the last patient visit is expected in May
2019. With an expected enrollment rate of 200 patients per
year, an enrollment period of 3 years, and a minimum follow-
up period of 18 months, the first data release is projected to
occur in early 2020. The end of the study is defined as the time
when all randomized patients will show evidence of second
disease progression or will be discontinued from treatment,
per protocol, for toxicity or medical decision.
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Fig. 2 Study schemas for key ongoing trials investigating triplet
chemotherapy + biologics as first-line therapy in patients with mCRC.
(a) CHARTA phase II study (NCT01321957): FOLFOX and
bevacizumab with or without irinotecan [38]. (b) TRIBE-2 phase III
study: first-line FOLFOXIRI + bevacizumab, followed by
reintroduction of FOLFOXIRI + bevacizumab at progression vs.
FOLFOX + bevacizumab, followed by FOLFIRI + bevacizumab at pro-
gression, in first- and second-line treatment of unresectable mCRC
(TRIBE-2 clinical protocol). (c) METHEP-2 phase 2 study: FOLFIRI
or FOLFOX vs. FOLFIRINOX + bevacizumab or cetuximab
(NCT01442935). (d) STEAM phase 2 study: FOLFOXIRI +
bevacizumab (STEAM study protocol; NCT01765582). aStrata: clinical
groups (unresectable liver and/or lung metastasis potentially resectable
after treatment-induced downsizing, comorbidities allowing surgery; or
multiple metastasis, rapid progression, risk of rapid deterioration, unlikely
to become resectable; or never resectable and no symptoms or risk of
deterioration). bThe third and subsequent lines of treatment will be at
investigators’ choice. cBiologic agent is chosen according to tumor
KRAS status: bevacizumab for mutated KRAS, cetuximab for wild-
type KRAS. dPatients stratified for extent of metastatic disease (liver-
limited disease vs. non-liver-limited disease), primary tumor location
(right vs. left), and study center. esFOLFOXIRI (sequential
FOLFOXIRI) consists of alternating 4-week administrations (2×2-week
cycles) of FOLFOX and FOLFIRI. fIf the patient exhibits a good
response (complete response, partial response, or stable disease) and
still tolerates the regimen after 4 months of induction, the therapy can
be continued at the investigator's discretion for up to an additional
2 months (discussion with the Medical Monitor). gTreatment will
continue until progression, death, withdrawal of consent, or
unacceptable toxicities occur, according to dose modification guidance.
5-FU, 5-fluorouracil; ECOG, Eastern Cooperative Oncology Group;
FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFOX, 5-
fluorouracil, leucovorin, oxaliplatin; FOLFOXIRI, 5-fluorouracil,
leucovorin, oxaliplatin, irinotecan; LV, leucovorin; mCRC, metastatic
colorectal cancer; PD, progressive disease; sFOLFOXIRI, sequential 5-
fluorouracil, leucovorin, oxaliplatin, irinotecan
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4.2.3 Chemotherapies Associated with Targeted Therapies
on the Resection Rate of Hepatic Metastases (METHEP-2,
NCT01442935)
METHEP-2 (ACCORD 21–PRODIGE 14) trial is a phase II
randomized trial comparing doublet chemotherapy
(FOLFIRI/FOLFOX) with FOLFIRINOX combined with a
targeted therapy selected according to RAS mutational status
(i.e., bevacizumab for tumors with mutated KRAS; cetuximab
for wild-type KRAS) in patients with colorectal cancer and
initially unresectable liver metastases (Fig. 2c). The primary
endpoint is the comparison of secondary resection rates of
liver metastases between the control arm (doublet chemother-
apy + targeted therapy) vs. the experimental arm (triplet che-
motherapy + targeted therapy). The total number of patients is
256, and accrual was closed in May 2015. Translational stud-
ies are planned.
4.2.4 A Study of FOLFOXIRI + Bevacizumab Regimens
(Concurrent and Sequential) vs. FOLFOX + Bevacizumab
in First-line mCRC (Sequential Triplet and Bevacizumab
Maintenance; STEAM, NCT01765582)
It has been suggested that alternating treatment every two
cycles with FOLFOX + bevacizumab and FOLFIRI +
bevacizumab (i.e., sequential FOLFOXIRI + bevacizumab)
may improve the tolerability of the regimen without affect-
ing efficacy [56], and may help guide the choice of
second-line treatment. The phase II STEAM trial is inves-
tigating concurrent or sequential FOLFOXIRI +
bevacizumab vs. FOLFOX + bevacizumab in patients with
previously untreated mCRC (Fig. 2d). The coprimary effi-
cacy endpoints are overall response rate and PFS.
At the time of a preplanned interim safety analysis, 94
patients were randomized (intention-to-treat population), and
93 patients received at least one dose of study treatment (safe-
ty population) [57]. The overall adverse event profile of
FOLFOXIRI + bevacizumab was similar to that observed in
previous trials of triplet chemotherapy + bevacizumab, includ-
ing the TRIBE study [58], although the incidence of
treatment-emergent adverse events in the sequential
FOLFOXIRI + bevacizumab group were similar to those in
the FOLFOX + bevacizumab arm. This suggests that alternat-
ing treatment with FOLFOX + bevacizumab and FOLFIRI +
bevacizumab may improve the tolerability of the regimen,
although more mature data are needed to confirm these results
[57].
Data from these ongoing studies and others may shed
light on how different combinations of chemotherapeutic
agents administered in combination with bevacizumab,
and how the use of these combinations across multiple
lines of therapy impacts efficacy and safety in patients
with mCRC.
5 A Practical Guide for the Administration of Triplet
Chemotherapy in Combination with Bevacizumab
5.1 Frequently Occurring Adverse Events
Adverse events are common in patients treated with chemo-
therapeutic agents. Particular associations include diarrhea
with 5-FU and irinotecan [59–61], neutropenia with irinotecan
[60], and neurotoxicity with oxaliplatin [62]. With treatment
intensification to triplet chemotherapy combined with
bevacizumab, the most common adverse events were neutro-
penia, febrile neutropenia, stomatitis, and diarrhea [37–39,
43].
Given the known safety profile of triplet chemotherapy ±
bevacizumab, the FOLFOXIRI + bevacizumab regimen
should only be considered for patients <75 years old with an
ECOG performance status of ≤1, as these patients have a
lower risk of requiring dose reductions or treatment discontin-
uations due to chemotherapy-related toxicities, compared with
older patients and those that have an ECOG performance sta-
tus ≥2. Patients aged 71–75 years should have an ECOG
performance status <2 if FOLFOXIRI + bevacizumab is con-
sidered, while those >75 years should not be treated with the
regimen. Alternatively, physicians may initiate treatment
using a dose step-up approach with an upfront dose of 5-FU
and/or irinotecan at 75 % of the approved dose, followed by
escalation to the approved dose if no significant toxicity
occurs.
5.2 Management of Treatment-related Adverse Events
Early recognition and the active management of treatment-
related adverse events are critical for the overall care of pa-
tients [39]. Rapid intervention, particularly in the case of gas-
trointestinal adverse events, may improve tolerability [61],
with the potential to decrease the need to reduce or interrupt
treatment. Management options include symptomatic drug
treatment (e.g., loperamide, granulocyte colony stimulating
factor, and prophylactic antibiotics for diarrhea or antihyper-
tensive agents for blood pressure control), immediate support-
ive care as needed, or dose reduction or interruption [63, 64].
Notably, polymorphisms in drug metabolism genes may
leave some patients susceptible to severe adverse events
[65]. Patients experiencing unexpected toxicity during treat-
ment may be genotyped for polymorphisms known to impact
tolerability to various agents [66]. For example, it is recom-
mended that patients with loss-of-function mutations
in dihydropyr imidine dehydrogenase or ur id ine
diphosphoglucuronic genes receive reduced doses of 5-FU
or irinotecan, respectively [65, 67].
Table 3 provides protocol-based recommendations for the
management of grade 3 or 4 adverse events that were com-
monly observed in clinical trials of patients with mCRC who
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were treated with bevacizumab in combination with triplet
chemotherapy; guidance for dose reduction/interruption or
discontinuation of agents, when prudent, is also provided.
5.2.1 Diarrhea
It is estimated that more than half of all patients receiving
chemotherapy for CRC experience diarrhea of any grade
[59, 68, 69]. Severe (grade 3 and 4) diarrhea, observed in
approximately one-fifth of the patients in the TRIBE study,
imparts a significant health-related burden on the quality of
life of patients.
Uncomplicated diarrhea may be managed through support-
ive care, including dietary modifications, and commonly used
drugs [70, 71]. Several pharmacologic agents have been in-
vestigated for the prevention of treatment-induced diarrhea,
but, to date, none have proven efficacy [71]. Loperamide (or
codeine as an alternative), which works by binding to recep-
tors in the gastrointestinal tract to slow transit time [61], is
appropriate for the initial treatment of diarrhea [71]. For per-
sistent diarrhea, despite loperamide treatment (or as initial
treatment for grade 3 or 4 diarrhea), octreotide or tincture of
opiummay be effective [63, 71]. Racecadotril, which does not
slow transit time, may be recommended in acute cases of
diarrhea for which infection is suspected [72].
Probiotics, including lactobacillus and bifidobacterium,
are thought to restore the balance of intestinal microbiota
disrupted by chemotherapy [73, 74] and have been shown
to reduce the incidence of grade ≥2 diarrhea [75, 76].
The Multinational Association of Supportive Care in
Cancer/International Society of Oral Oncology has there-
fore recently recommended probiotic use for the preven-
tion of diarrhea [77]. However, caution should be
exercised in immunocompromised patients with cancer,
but rare or no cases of sepsis have been observed in this
patient population [75, 76].
5.2.2 Nausea/Vomiting
Nausea and vomiting (emesis) occur in approximately 29 %
and 11 % of overall patients, respectively, receiving chemo-
therapy [78]. In the OLIVIA and TRIBE trials, patients were
treated prophylactically (starting day 1 of chemotherapy) with
5-hydroxytryptamine-3 antagonists (i.e., palonosetron), dexa-
methasone, or with other antiemetics. Of note, the incidence
of grade 3/4 nausea and vomiting was not significantly in-
creased with the use of triplet + bevacizumab compared
with doublet + bevacizumab in the two available randomized
studies [37, 39]. In general, palonosetron and dexamethasone
are recommended for patients receiving moderately
emetogenic chemotherapy [79, 80].
5.2.3 Stomatitis/Mucositis
Guidelines for management of oral mucositis include main-
taining oral hygiene by brushing with a soft toothbrush that is
frequently replaced, flossing, and rinsing with saline and ap-
plying topical anesthetics or transdermal fentanyl; painful mu-
cositis may be treated with doxepin [81, 82]. While mucositis
prophylaxis may include cryotherapy [81], it should be
avoided in patients receiving oxaliplatin, as it may exacerbate
acute neurologic symptoms [62] and cause laryngospasm for
up to 48 h.
Patients with gastrointestinal mucositis may be treated with
ranitidine or omeprazole to prevent epigastric pain following
5-FU treatment [81]. Adequate hydration and the potential for
transient lactose intolerance and presence of bacterial patho-
gens should also be considered for at-risk patients [81].
5.2.4 Neutropenia
Current guidelines recommend that primary granulocyte
colony-stimulating factor (G-CSF) prophylaxis be used when
the overall risk (i.e., due to regimen and patient factors) for
febrile neutropenia is ≥20% [83]. However, the use of G-CSF
to treat febrile neutropenia should be carefully considered, as
studies have shown that G-CSF has been overutilized in pa-
tients with low risk of febrile neutropenia, but underutilized in
those with high risk [84, 85]. Individual patient factors are to
be considered in cases with a 10–20 % risk, while G-CSF is
not indicated for patients with a risk <10 % [83]. The rate of
febrile neutropenia with FOLFOXIRI and bevacizumab is re-
ported to be 8.8–13 %; therefore, a general primary GCSF
prophylaxis is not necessary [37, 39]. However, G-CSF has
also been shown to be effective as a secondary prophylaxis in
patients who experienced febrile neutropenia in a previous
treatment cycle [86]. If the goal is to induce rapid regression
of liver metastases to achieve secondary resection, G-CSF
may be considered for primary prophylaxis to avoid delays
or dose reductions in chemotherapy administration [17].
5.2.5 Hypertension
Because patients receiving bevacizumab have an increased in-
cidence of severe hypertension, blood pressure monitoring ev-
ery 2–3 weeks is recommended [24], and antihypertensive
treatment should be provided [24] on the basis of recommend-
ed guidelines [87]. Patients with grade 2 hypertension may be
treated with antihypertensive monotherapy (e.g., an
angiotensin-converting enzyme inhibitor), and may resume
bevacizumab treatment once blood pressure is controlled to
<150/100 mm Hg. Patients experiencing grade 3 hypertension
may require more than one antihypertensive agent or more
intensive therapy (i.e., a diuretic or calcium channel blocker).
Bevacizumab treatment should be suspended in patients with
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grade 3 hypertension that is not controlled by medical manage-
ment, and it should be discontinued in patients with hyperten-
sive crisis or hypertensive encephalopathy.
5.3 Dosage Reductions, Interruptions,
or Discontinuations
5.3.1 Bevacizumab
There are no recommended dose reductions for bevacizumab
[24], and no reductions were permitted in the phase II and
phase III clinical trials, which assessed bevacizumab in com-
bination with triplet chemotherapy. However, management of
adverse events, dose interruptions, or discontinuations of ther-
apy were recommended in the study protocols in certain, well-
defined situations (see Table 3). The prescribing information
recommends that bevacizumab be temporarily suspended in
patients with uncontrolled, severe hypertension and severe pro-
teinuria [24]. In addition to these recommendations, the proto-
cols also specified guidelines for the management of hyperten-
sion (i.e., angiotensin-converting enzyme inhibitor for grade 2
and a three-drug medication for grade 3) and monitoring of
proteinuria (see Table 3). Furthermore, because bevacizumab
impairs wound healing, suspension of bevacizumab dosing is
recommended prior to elective surgery (4 weeks according to
the guidelines of the US Food and Drug Administration and 6–
8weeks according to the guidelines of the EuropeanMedicines
Agency) until the patient is fully healed [24, 25]. In the event of
severe infusion reactions, gastrointestinal perforation, surgery
and wound-healing complications, severe arterial thromboem-
bolic events, life-threatening venous thromboembolism, hy-
pertensive crisis/encephalopathy, posterior reversible encepha-
lopathy syndrome, or nephritic syndrome, bevacizumab
should be permanently discontinued [24]. The protocols,
moreover, recommended a delay in bevacizumab dosing in
the event of grade 4 febrile neutropenia, a delay or discontin-
uation for grade ≥2 pulmonary hemorrhage and grade 2
nonthromboembolic fistulae, and a discontinuation for any-
grade central nervous system (CNS) hemorrhage, grade ≥3
nonpulmonary and non-CNS hemorrhage, and any-grade
thromboembolic fistulae (see Table 3).
5.3.2 Triplet Chemotherapy
According to the TRIBE study protocol, dose adjustments were
recommended for all three components or a subset of the triplet
regimen for specific adverse events (see Table 3). Generally,
dose delays may be implemented until an adverse event re-
solves to a lower grade or baseline. For example, a dose should
be delayed in patients with grade ≥3 neutropenia occurring for
<5 days, grade ≥2 thrombocytopenia, or grade ≥2 diarrhea
and/or stomatitis. Dose reductions to 75 % are recommended
at the recurrence of a prior adverse event that led to a dose
reduction (e.g., third occurrence of neutropenia), or at the first
occurrence of a higher-grade adverse event (e.g., grade 4 neu-
tropenia lasting ≥5 days, febrile neutropenia, grade ≥3 throm-
bocytopenia, or grade ≥3 related significant organ toxicities).
Triplet chemotherapy should be discontinued for grade 4
thrombocytopenia. For other adverse events, dose modifica-
tions of individual components of the triplet regimen are rec-
ommended. For example, 5-FU/LV dose may be reduced for
grade ≥3 hand–foot syndrome or mucositis, or after a second
occurrence for these events of grade ≥2. Furthermore, for per-
sistent, unresolved grade ≥2 neurosensory events, oxaliplatin is
recommended to be temporarily discontinued [62]. For the sec-
ond occurrence of diarrhea that requires a dose delay or the first
occurrence of a grade ≥3 event, both irinotecan and 5-FU/LV
may be reduced to 75 % of the starting dose.
6 Conclusions
Data from phase II and phase III clinical trials of triplet che-
motherapy in combination with bevacizumab suggest that ef-
ficacy and/or resection rates are improved comparedwith dou-
blet chemotherapy + bevacizumab [37, 39]. Adverse events
were manageable given the proper selection of patients and
the careful monitoring for severe adverse events [37, 39]. We
have herein described the clinical applicability of this regimen
and provided a guide for its usage in first-line mCRC patients.
Additional trials to evaluate efficacy, tolerability, and
patient-reported outcomes of FOLFOXIRI + targeted biologic
agents across multiple lines of treatment and in different set-
tings (i.e., potentially resectable patients) are underway.
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